Neoadjuvant PD-1 LAG-3 Antibody Melanoma Trial Results

Here’s a breakdown⁤ of teh key ‍findings ⁤from the‍ provided text regarding⁤ ctDNA (circulating tumor DNA) and its relationship to treatment response:

* High Detection Rate: ctDNA was detected in a very high percentage of ⁤patients (89.7%) even at early disease stages. This suggests ctDNA is a sensitive marker of disease presence.
* ctDNA Clearance & ⁢pathological Response: ⁢ There’s a strong correlation between⁢ achieving a pathological response (meaning cancer cells are ‍not found or considerably reduced after treatment) and clearing ctDNA.
*⁤ Good Response (pCR/npCR/pPR): 68% of patients ⁤with any degree of pathological response achieved ctDNA clearance by week 7 (before surgery).
⁢ * No Response (pNR): Only 25% of patients with no ⁤pathological response achieved ctDNA clearance.
*⁢ CPI Treatment & ctDNA Clearance: The use of CPI (likely ⁢checkpoint inhibitor) treatment led to increasing rates of⁣ ctDNA clearance:
* After 1 cycle: 50% of patients⁢ with pCR⁢ had ctDNA clearance.
* After 2 cycles: 77.3% of patients with pCR⁤ had ctDNA⁢ clearance.
* Figure 4: The figure illustrates the longitudinal changes in ⁤ctDNA levels over ⁤time, showing how ctDNA status changes ‍with treatment and in relation ⁢to surgical ⁣intervention (TLND – Tumor Lymph Node Dissection). it visually demonstrates the⁤ correlation ‍between treatment, ctDNA clearance, and pathological response.

In essence, the study ‍suggests that ctDNA is a promising ⁤biomarker for monitoring treatment response.Clearance of ctDNA is associated with better pathological outcomes, and CPI treatment appears to drive ctDNA clearance in patients⁤ who respond ⁣well ⁤to therapy.